SCHEMBL4592655

SCHEMBL4592655

Oc1ccc(-c2nc3ccccc3s2)cc1F

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 10/20 0.64
RAB9A P51151 9/20 0.64
MAPT P10636 8/20 0.64
SMN1; SMN2 Q16637 6/20 0.64
ALDH1A1 P00352 5/20 0.64
GLA P06280 4/20 0.64
GAA P10253 4/20 0.64
HPGD P15428 3/20 0.64
PPARG P37231 1/20 0.64
NCOA2 Q15596 1/20 0.64
NCOA1 Q15788 1/20 0.64
NPC1 O15118 9/20 0.62
LMNA P02545 3/20 0.62
HSD17B10 Q99714 4/20 0.61
TP53 P04637 3/20 0.61
NFKB1 P19838 3/20 0.61
NFKB2 Q00653 3/20 0.61
RELA Q04206 3/20 0.61
POLB P06746 2/20 0.61
KMT2A Q03164 5/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30466258 0.86 KDM4E (0.69) KDM4ERAB9AMAPTSMN1; SMN2ALDH1A1
SCHEMBL12470903 0.86 KDM4E (0.69) KDM4ERAB9AMAPTSMN1; SMN2ALDH1A1
SCHEMBL25288484 0.83 KDM4E (0.71) KDM4ERAB9AMAPTSMN1; SMN2ALDH1A1
SCHEMBL8373442 0.82 MAPT (0.68) KDM4ERAB9AMAPTSMN1; SMN2ALDH1A1
SCHEMBL15952333 0.82 APP (0.55) KDM4ERAB9AMAPTSMN1; SMN2ALDH1A1
SCHEMBL4592891 0.82 APP (0.69) KDM4ERAB9AMAPTSMN1; SMN2ALDH1A1
SCHEMBL12471564 0.82 KDM4E (0.64) KDM4ERAB9AMAPTSMN1; SMN2ALDH1A1
SCHEMBL11193289 0.82 RAB9A (0.66) KDM4ERAB9AMAPTSMN1; SMN2ALDH1A1
SCHEMBL30466256 0.82 MAPT (0.68) KDM4ERAB9AMAPTSMN1; SMN2ALDH1A1
SCHEMBL11325434 0.82 MAPT (0.64) KDM4ERAB9AMAPTSMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1910349-A1 2-ARYLBENZOTHIAZOLES AND USES THEREOF 4SC AG (DE) 2008-04-16 EP disclosed
WO-2007009524-A1 2-ARYLBENZOTHIAZOLES AND USES THEREOF 4SC AG (DE) 2007-01-25 WO disclosed
US-20070021446-A1 2-arylbenzothiazole analogues and uses thereof 4SC AG (DE) 2007-01-25 US disclosed
EP-1746096-A1 2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer 4SC AG (DE) 2007-01-24 EP disclosed
EP-1746096-A1 2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer 4SC AG (DE) 2007-01-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070021446-A1 2-arylbenzothiazole analogues and uses thereof NR2E1, NR2E3, NR0B2 KDM4E 2243/4885RAB9A 3722/4885MAPT 4822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.